Duke Street Bio
  • About
  • Science
    • R&D Programs
    • Publications
  • People
  • Pipeline
  • News
  • Contact
Select Page
Duke Street Bio Announces First Patient Dosed in Phase I Trial with DSB2455, a Next Generation PARP1 Selective Inhibitor for the Treatment of Solid Tumours

Duke Street Bio Announces First Patient Dosed in Phase I Trial with DSB2455, a Next Generation PARP1 Selective Inhibitor for the Treatment of Solid Tumours

by Barry McGuinness | Dec 2, 2024 | Announcement, Precision Oncology

First Patient Dosed in Phase I Trial with DSB2455 Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the first patient has been dosed in a Phase I trial evaluating the highly...

Recent Posts

  • Duke Street Bio Announces First Patient Dosed in Phase I Trial with DSB2455, a Next Generation PARP1 Selective Inhibitor for the Treatment of Solid Tumours
  • Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial
  • Duke Street Bio Announces Appointment of Chief Medical Officer
  • Next Gen PARP1 & PARP7 inhibitor programmes

Recent Comments

    © Duke Street Bio Ltd | hello@dukesb.com | Privacy